ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

South Carolina Politicos Join Hollings Oncology Center Section

October 30, 1992

Implantable Drug Delivery Device Offers Better Pain Relief

September 27, 2002

In Brief: LEO Sachs To Receive 1983 Bristol-Myers Award; 50 Percent Current Rate Achievable Now: Tylor

April 1, 1983

Center Directors Offer Each Other Advice On how To Prepare for, Handle Reviewers

December 16, 1977

FDA Proposes New Nonclinical Lab Regs

November 26, 1976

MGMT Gene Can Determine Disease Aggressiveness

June 24, 2011